- Home
- FRHC vs BIO Comparison
FRHC vs BIO Comparison
Compare FRHC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | BIO |
|---|---|---|
| Founded | N/A | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.1B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | FRHC | BIO |
|---|---|---|
| Price | $167.92 | $364.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $328.33 |
| AVG Volume (30 Days) | 75.6K | ★ 256.4K |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.29 | ★ 142.61 |
| EPS | ★ 0.52 | N/A |
| Revenue | $2,191,291,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.13 |
| P/E Ratio | $325.06 | ★ N/A |
| Revenue Growth | ★ 6.86 | 0.65 |
| 52 Week Low | $107.98 | $236.73 |
| 52 Week High | $178.00 | $396.23 |
Technical Indicators
Market Signals| Indicator | FRHC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 45.64 |
| Support Level | $161.32 | $358.85 |
| Resistance Level | $175.47 | $392.81 |
| Average True Range (ATR) | 5.79 | 12.52 |
| MACD | -0.86 | -2.22 |
| Stochastic Oscillator | 34.74 | 30.27 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.